China's Technology: From National-Level Products to Breakthroughs in Specialized Fields
BEIJING,Feb. 18,2025-- A news report from sinolub: In the era of rapid digitalization and intelligent development,China\'s technology is rising on the global stage at an unprecedented speed. From arti
\'CJRB-201\',a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects,has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains.
GoDaddy Airo Delivers website creation,logo design and digital marketing strategies for entrepreneurs to get started online quickly
PharmaBlock Launches Commercial GMP Workshop 503 at Zhejiang Site
NANJING,China,Feb. 18,2025-- PharmaBlock Sciences (Nanjing),Inc. (Stock code: 300725.SZSE) has announced the official launch of its commercial GMP Workshop 503 (W503) at PharmaBlock Zhejiang. The new
Stryker launches ProCeed hospital bed
New hospital bed helps caregivers deliver efficient and quality care in markets outside the U.S. PORTAGE,Mich.,Feb. 17,2025-- Stryker (NYSE:SYK),a global leader in medical technologies,announced the
TAIPEI,Feb. 17,2025-- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311,the world\'s first Apixaban oral dissolving film (ODF). The study confirmed that TAH
Minish Holds First Seminar in Japan with Great Success - Over 100 Dentists in Attendance
"Impressed by Extensive Full-Mouth Rehabilitation Cases","Anti-Aging Effects Highly Praised"
Reolink Makes Wireless Security Camera Systems Accessible to All Homes
LOS ANGELES,Feb. 17,2025-- Every homeowner deserves peace of mind when it comes to home security. Reolink,an innovative leader in intelligent visual technology for the home,brings the Wireless Securi
Duke and Duke-NUS forge new frontiers in climate health research with S$1million funding
The two institutions awarded more than S$1 million to accelerate five promising areas of research collaboration
SUZHOU,China,Feb. 13,2025-- Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 bi